• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

    226.12 -6.52 (-2.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,393,022
    Open 231.91
    Bid (Size) 185.00 (100)
    Ask (Size) 238.00 (100)
    Prev. Close 232.64
    Today's Range 224.23 - 232.69
    52wk Range 105.00 - 243.32
    Shares Outstanding 62,311,104
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Healthcare Stocks We Think Twice About
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
    Via StockStory

    Performance

    YTD
    +30.6%
    +30.6%
    1 Month
    +8.7%
    +8.7%
    3 Month
    +18.7%
    +18.7%
    6 Month
    +31.4%
    +31.4%
    1 Year
    +108.8%
    +108.8%

    More News

    Read More
    News headline image
    3 Mid-Cap Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    Is Marriott Stock a Buy After GMT Capital Initiated a Position Worth Over $66 Million? ↗
    Via The Motley Fool
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat ↗
    Via Chartmill
    News headline image
    Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
    Via StockStory
    News headline image
    JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals
    Via StockStory
    News headline image
    Jazz (JAZZ) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Beats Q4 Estimates but 2026 Guidance Tempers Gains ↗
    Via Chartmill
    News headline image
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
    Via StockStory
    News headline image
    Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Overrated Stocks with Warning Signs
    Via StockStory
    News headline image
    3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
    Via StockStory
    News headline image
    Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
    Via MarketMinute
    News headline image
    The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    1 Value Stock to Research Further and 2 We Ignore
    Via StockStory
    News headline image
    3 Healthcare Stocks Walking a Fine Line
    Via StockStory
    News headline image
    Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
    Via StockStory
    Topics Artificial Intelligence Supply Chain
    News headline image
    Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales
    Via StockStory
    News headline image
    Jazz Pharmaceuticals Earnings: What To Look For From JAZZ
    Via StockStory
    Topics Artificial Intelligence Government World Trade
    News headline image
    1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
    Via StockStory
    News headline image
    1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid
    Via StockStory

    Frequently Asked Questions

    Is Jazz Pharmaceuticals plc - Ordinary Shares publicly traded?
    Yes, Jazz Pharmaceuticals plc - Ordinary Shares is publicly traded.
    What exchange does Jazz Pharmaceuticals plc - Ordinary Shares trade on?
    Jazz Pharmaceuticals plc - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares?
    The ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares is JAZZ on the Nasdaq Stock Market
    What is the current price of Jazz Pharmaceuticals plc - Ordinary Shares?
    The current price of Jazz Pharmaceuticals plc - Ordinary Shares is 226.12
    When was Jazz Pharmaceuticals plc - Ordinary Shares last traded?
    The last trade of Jazz Pharmaceuticals plc - Ordinary Shares was at 06/02/26 04:00 PM ET
    What is the market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares?
    The market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares is 14.09B
    How many shares of Jazz Pharmaceuticals plc - Ordinary Shares are outstanding?
    Jazz Pharmaceuticals plc - Ordinary Shares has 14B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.